Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist
<p>Abstract</p> <p>Pharmacodynamic assays are important in clinical trial design to investigate the relationship between drug concentration (pharmacokinetics) and drug "effect' or biological activity. Increasingly flow cytometry is being used to examine the pharmacodynami...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-12-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://www.translational-medicine.com/content/6/1/76 |
id |
doaj-543e11d33b0b4285ae47e1b09275defe |
---|---|
record_format |
Article |
spelling |
doaj-543e11d33b0b4285ae47e1b09275defe2020-11-24T21:44:35ZengBMCJournal of Translational Medicine1479-58762008-12-01617610.1186/1479-5876-6-76Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonistLackey AlanWyant TimothyGreen Marie<p>Abstract</p> <p>Pharmacodynamic assays are important in clinical trial design to investigate the relationship between drug concentration (pharmacokinetics) and drug "effect' or biological activity. Increasingly flow cytometry is being used to examine the pharmacodynamic effect of new drug entities. However, to date, the analytical validation of cytometry based assays is limited and there is no suitable guidance for method validation of flow cytometry-based pharmacodynamic assays. Here we report the validation of a flow cytometry-based chemokine internalization assay for use in evaluating the effect of a receptor antagonist in clinical trials. The assay method was validated by examining the stability of the reagent, assay robustness, sensitivity, repeatability and reproducibility precision. Experimental results show the assay reagent was stable over 26 weeks. The assay demonstrated a sensitivity to distinguish 0.005 μg/ml of a CCR2 antagonist with a %CV of 13.3%. The intra-assay repeatability was less than 15% with an inter-assay repeatability of less than 20%. In vivo study results demonstrated that the assay was consistent and a reliable measure of antagonist activity.</p> http://www.translational-medicine.com/content/6/1/76 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lackey Alan Wyant Timothy Green Marie |
spellingShingle |
Lackey Alan Wyant Timothy Green Marie Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist Journal of Translational Medicine |
author_facet |
Lackey Alan Wyant Timothy Green Marie |
author_sort |
Lackey Alan |
title |
Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist |
title_short |
Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist |
title_full |
Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist |
title_fullStr |
Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist |
title_full_unstemmed |
Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist |
title_sort |
validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist |
publisher |
BMC |
series |
Journal of Translational Medicine |
issn |
1479-5876 |
publishDate |
2008-12-01 |
description |
<p>Abstract</p> <p>Pharmacodynamic assays are important in clinical trial design to investigate the relationship between drug concentration (pharmacokinetics) and drug "effect' or biological activity. Increasingly flow cytometry is being used to examine the pharmacodynamic effect of new drug entities. However, to date, the analytical validation of cytometry based assays is limited and there is no suitable guidance for method validation of flow cytometry-based pharmacodynamic assays. Here we report the validation of a flow cytometry-based chemokine internalization assay for use in evaluating the effect of a receptor antagonist in clinical trials. The assay method was validated by examining the stability of the reagent, assay robustness, sensitivity, repeatability and reproducibility precision. Experimental results show the assay reagent was stable over 26 weeks. The assay demonstrated a sensitivity to distinguish 0.005 μg/ml of a CCR2 antagonist with a %CV of 13.3%. The intra-assay repeatability was less than 15% with an inter-assay repeatability of less than 20%. In vivo study results demonstrated that the assay was consistent and a reliable measure of antagonist activity.</p> |
url |
http://www.translational-medicine.com/content/6/1/76 |
work_keys_str_mv |
AT lackeyalan validationofaflowcytometrybasedchemokineinternalizationassayforuseinevaluatingthepharmacodynamicresponsetoareceptorantagonist AT wyanttimothy validationofaflowcytometrybasedchemokineinternalizationassayforuseinevaluatingthepharmacodynamicresponsetoareceptorantagonist AT greenmarie validationofaflowcytometrybasedchemokineinternalizationassayforuseinevaluatingthepharmacodynamicresponsetoareceptorantagonist |
_version_ |
1725909244203499520 |